Medifast Inc (MED) Stock Price, Quote & News

Company Profile

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. It also provides bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding,...

Industry: Personal Services

Sector: Consumer Cyclical

Phone: 410 581 8042

Website: medifastinc.com

Address:

100 International Drive, 18th Floor, Baltimore, United States

Amolosricha1 Feb. 2 at 8:21 PM

$MED Is there really a chance that this could rebound significantly... The return gained would be crazy from this stock alone. Going from $12 to something like over $100.

0 · Reply

justcomments Jan. 30 at 8:59 PM

$MED hey, bulls, wake up people. This could be the last bad quarter in this thing. It is very hard to change the prevailing opinion of consumers, but when they get pissed - the incoming wave can be overwhelming. Can you imagine what might happen, if all these semi obese dudes figure GLP1 drugs are really killing them? Sooner or later someone will pick it up in the media, run coverage of the lawsuits, publish the injuries and we are good to go. MED can have a comeback. I am counting on it. I wouldn't be surprised to see the stock back at a $100 some time soon. Wouldn't that be nice?

1 · Reply

justcomments Jan. 30 at 4:57 AM

$MED I am absolutely shocked by the details in that article. $MED to the moon now.

0 · Reply

justcomments Jan. 30 at 4:56 AM

$MED you guys won't believe it - ZH wrote an article about GLP1. Look: https://www.zerohedge.com/medical/my-colon-literally-blew-thousands-sue-over-glp-1-weight-loss-drug-side-effects

0 · Reply

Amolosricha1 Jan. 28 at 6:33 PM

$NVO $LLY $MED After 1 y of taking the drug nearly everybody quits the drug because of the severe side effect. Now, people are trying to sue the drug manufacturer. After 2 years of quitting the weight loss drugs. People regain their weight. Weight loss drug sucks.

4 · Reply

ZacksResearch Jan. 22 at 6:02 PM

$MED’s Q4 guidance signals struggle 📉 Revenue is projected to be $65M-$80M with a loss per share of 70 cents to $1.25. In Q3, revenue fell 36.2% YoY, driven by a 35% drop in active earning coaches. Understand the challenges and potential turnaround here 👉 https://www.zacks.com/stock/news/2821448/medifasts-q4-guidance-remains-weak-when-does-growth-return?cid=sm-stocktwits-2-2821448-body-30112&ADID=SYND_STOCKTWITS_TWEET_2_2821448_BODY_30112

0 · Reply

ZacksResearch Jan. 22 at 5:02 PM

Weak guidance, big question mark — when does $MED actually grow again? ⚠️ Medifast is guiding to a weak Q4 after steep revenue declines, even as it pivots toward metabolic health in an effort to stabilize results and set up a recovery. Find out when growth could realistically return 👉 https://www.zacks.com/stock/news/2821448/medifasts-q4-guidance-remains-weak-when-does-growth-return?cid=sm-stocktwits-2-2821448-teaser-30079&ADID=SYND_STOCKTWITS_TWEET_2_2821448_TEASER_30079

0 · Reply

Amolosricha1 Jan. 20 at 1:30 AM

$MED This is a great jouney. I am happy for her. The results she has achieved with OPTAVIA are excellent. https://www.businesswire.com/news/home/20260116786138/en/People-Magazine-Spotlights-Tiffany-Howards-Metabolic-Health-Journey-with-OPTAVIA

0 · Reply

justcomments Jan. 9 at 7:07 PM

$MED GLP1=Pancreatitis cancer. Thyroid cancer. Kidney damage. Heart failure. Gastrointestinal paralysis. Eye problems. BUY MED

0 · Reply

Hanse2014 Jan. 9 at 4:55 PM

$MED :As 2025 came to a close, our teams across Medifast took time to gather together and honor what we have accomplished throughout the year. Thank you to all our team members for bringing momentum into 2026. From our Medifast team to you, wishing you a strong start to the new year!" I want to see momentum!!

0 · Reply

People Magazine Spotlights Tiffany Howard's Metabolic Health Journey with OPTAVIA®

Jan 15, 2026, 8:30 AM EST - 18 days ago

OPTAVIA® Premieres Second Docuseries Episode “Health by Design: Spain” Exploring Metabolic Health and Longevity

Jan 5, 2026, 9:00 AM EST - 4 weeks ago

Medifast Announces Planned Leadership Transition

Dec 9, 2025, 8:30 AM EST - 7 weeks ago

OPTAVIA Survey Reveals 80% of Americans Lack Understanding of Metabolic Health Despite Its Major Impact to Overall Health and Wellbeing

Nov 13, 2025, 4:30 PM EST - 2 months ago

Medifast Scientific & Clinical Affairs Team Showcases New Research in Metabolic Health at ObesityWeek Conference

Nov 3, 2025, 6:36 PM EST - 3 months ago

Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:05 PM EST - 3 months ago

Medifast Announces Third Quarter 2025 Financial Results

Oct 27, 2025, 8:30 AM EDT - 3 months ago

Medifast Announces Strategic Shift to Metabolic Health with the Introduction of Metabolic Synchronization™

Oct 21, 2025, 10:00 AM EDT - 3 months ago

Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2025

Sep 15, 2025, 8:30 AM EDT - 5 months ago

Evidence Links 5 & 1 Plan® to Improved Metabolic Health Outcomes

Aug 4, 2025, 11:56 PM EDT - 6 months ago

Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:05 PM EDT - 6 months ago

Medifast Announces Second Quarter 2025 Financial Results

LFMD

Jul 21, 2025, 4:05 PM EDT - 7 months ago

Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2025

Jul 3, 2025, 2:48 AM EDT - 7 months ago

Medifast: Coach Surge Fuels Growth

Apr 28, 2025, 6:03 PM EDT - 10 months ago

Medifast, Inc. (MED) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 4:05 PM EDT - 10 months ago

Medifast Announces First Quarter 2025 Financial Results

LFMD

Mar 28, 2025, 9:21 AM EDT - 11 months ago

Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect

Feb 18, 2025, 7:06 PM EST - 1 year ago

Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 4:05 PM EST - 1 year ago

Medifast Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 4, 2025, 4:05 PM EST - 1 year ago

Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024

Jan 7, 2025, 8:30 AM EST - 1 year ago

Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND™ For GLP-1 Users & Those Looking for Help to Keep Weight Off

Dec 5, 2024, 8:30 AM EST - 1 year ago

Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications

Nov 6, 2024, 8:02 AM EST - 1 year ago

Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued

Nov 4, 2024, 5:56 PM EST - 1 year ago

Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

Medifast Announces Third Quarter 2024 Financial Results

Oct 21, 2024, 4:05 PM EDT - 1 year ago

Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2024

Oct 3, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.

Oct 1, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Medifast, Inc. For Possible Securities Fraud

Sep 30, 2024, 11:00 AM EDT - 1 year ago

Medifast Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Invited To Help The Schall Law Firm

Sep 28, 2024, 11:00 AM EDT - 1 year ago

Medifast Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

Sep 27, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.

Sep 26, 2024, 11:00 AM EDT - 1 year ago

Medifast Inc Is Being Investigated For Violating Securities Laws And Investors Are Urged To Contact The Schall Law Firm

Sep 25, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Medifast, Inc. For Possible Securities Fraud

Sep 24, 2024, 11:00 AM EDT - 1 year ago

Medifast Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

Sep 21, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Medifast, Inc. For Securities Fraud

Sep 20, 2024, 11:00 AM EDT - 1 year ago

Medifast Inc May Have Violated Securities Laws And Investors Are Urged To Help The Schall Law Firm Investigate

Sep 19, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Seeks Shareholder Participation In An Inquiry Into Medifast, Inc. For Possible Securities Fraud

Sep 17, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Seeks Shareholder Contributions To A Securities Fraud Inquiry Into Medifast, Inc.

Sep 15, 2024, 11:00 AM EDT - 1 year ago

Medifast, Inc. May Have Defrauded The Public And The Schall Law Firm Invites Stockholders To Join A Securities Fraud Inquiry

$The Schall Law Firm Is Investigating Medifast Inc's Possible Securities Related Infractions And Affected Investors Can Partake$

Sep 14, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Investigating Medifast Inc's Possible Securities Related Infractions And Affected Investors Can Partake

Sep 13, 2024, 11:00 AM EDT - 1 year ago

Medifast, Inc. May Have Committed Securities Fraud And Shareholders With Losses Are Urged To Contribute To The Schall Law Firm's Inquiry

$The Schall Law Firm Is Looking Into Medifast Inc's Possible Securities Law Infractions And Investors Are Invited To Reach Out$

Sep 12, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Medifast Inc's Possible Securities Law Infractions And Investors Are Invited To Reach Out

Sep 11, 2024, 11:00 AM EDT - 1 year ago

Medifast, Inc. May Have Committed Securities Fraud And Shareholders Can Join The Schall Law Firm's Inquiry

Sep 9, 2024, 11:00 AM EDT - 1 year ago

Medifast, Inc. Might Have Committed Securities Fraud And Impacted Shareholders Can Join The Schall Law Firm's Inquiry

Sep 7, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Whether Medifast Inc Violated Securities Laws And Investors Can Partake In The Investigation

Amolosricha1 Feb. 2 at 8:21 PM

$MED Is there really a chance that this could rebound significantly... The return gained would be crazy from this stock alone. Going from $12 to something like over $100.

0 · Reply

justcomments Jan. 30 at 8:59 PM

1 · Reply

justcomments Jan. 30 at 4:57 AM

$MED I am absolutely shocked by the details in that article. $MED to the moon now.

0 · Reply

justcomments Jan. 30 at 4:56 AM

$MED you guys won't believe it - ZH wrote an article about GLP1. Look: https://www.zerohedge.com/medical/my-colon-literally-blew-thousands-sue-over-glp-1-weight-loss-drug-side-effects

0 · Reply

Amolosricha1 Jan. 28 at 6:33 PM

4 · Reply

ZacksResearch Jan. 22 at 6:02 PM

0 · Reply

ZacksResearch Jan. 22 at 5:02 PM

0 · Reply

Amolosricha1 Jan. 20 at 1:30 AM

0 · Reply

justcomments Jan. 9 at 7:07 PM

$MED GLP1=Pancreatitis cancer. Thyroid cancer. Kidney damage. Heart failure. Gastrointestinal paralysis. Eye problems. BUY MED

0 · Reply

Hanse2014 Jan. 9 at 4:55 PM

0 · Reply

Amolosricha1 Jan. 9 at 2:51 AM

$NVO $LLY $MED I thought quitting diets lead to fast weight regain but quitting GLP-1 is even 4 times as fast. Weight loss drugs suck. this is the news: https://themorningnews.com/news/2026/01/08/weight-loss-drugs-end-weight-piled-back-4x-faster-than-dieting-study-finds/

7 · Reply

VanDownByTheRiver Jan. 8 at 8:26 PM

$LLY $MED $NVO

0 · Reply

Amolosricha1 Jan. 8 at 8:20 PM

$LLY $NVO $MED GLP-1 weight loss drug sucks. Everybody stops taking these drugs after 1 year. The side effects are just too high, so they quit. You can throw the pill into the garbage bin. People are not dumb, they will realize this. Death to the GLP-1 hype is comming...

3 · Reply

ZacksResearch Jan. 8 at 5:54 PM

$MED isn’t just chasing weight loss — it’s aiming bigger. 🚨 Metabolic health could be the real growth lever. Medifast is pivoting toward metabolic health, leaning on clinical data and new products to tackle root causes rather than relying solely on GLP-1 weight loss trends. Durable growth story or strategic reset? Find out here 👉 https://www.zacks.com/stock/news/2814558/medifast-shifts-to-metabolic-health-a-durable-growth-path?cid=sm-stocktwits-2-2814558-teaser-28065&ADID=SYND_STOCKTWITS_TWEET_2_2814558_TEASER_28065

0 · Reply

ZacksResearch Jan. 8 at 4:54 PM

$MED's strategic shift: Can its metabolic health focus lead to long-term growth? 🤔 Despite Medifast's innovative approach to metabolic health, shares are down 29.5% in 6 months and it holds a Zacks Rank #4 (Sell). The company's forward P/S ratio of 0.33 is well below the industry average. 📉 Full analysis here 👉 https://www.zacks.com/stock/news/2814558/medifast-shifts-to-metabolic-health-a-durable-growth-path?cid=sm-stocktwits-2-2814558-body-28067&ADID=SYND_STOCKTWITS_TWEET_2_2814558_BODY_28067

0 · Reply

justcomments Jan. 7 at 10:39 PM

$MED looks like a tax loss harvesting candidate for 2026 return. I was hoping for a better outcome, but this is almost hopeless.

0 · Reply

Mr__G Jan. 5 at 2:33 PM

$MED Finaly a new CEO ! Thank the Lord.

1 · Reply

ZacksResearch Dec. 30 at 7:11 PM

Medifast's $MED shares down 28.2% in 6 months — Is it time to reconsider? 🤔 🔍 MED is shifting from weight-loss to metabolic health, but it carries a Zacks Rank #4 (Sell). 📉 Forward P/S ratio of 0.33 vs. industry average of 1.05 suggests undervaluation, yet earnings are projected to decline. Understand the risks before investing in MED 👉 https://www.zacks.com/stock/news/2810456/medifast-new-product-line-planned-can-innovation-reignite-demand?cid=sm-stocktwits-2-2810456-body-26908&ADID=SYND_STOCKTWITS_TWEET_2_2810456_BODY_26908

0 · Reply

ZacksResearch Dec. 30 at 6:11 PM

New product launch for MED — can innovation spark demand again? 👀 This could be a turning point. $MED plans a new product line rooted in metabolic synchronization science, upgrading its core offerings as it shifts beyond weight loss — a strategic move aimed at refreshing demand. Can this reset the growth story? Find out here 👉 https://www.zacks.com/stock/news/2810456/medifast-new-product-line-planned-can-innovation-reignite-demand?cid=sm-stocktwits-2-2810456-teaser-26895&ADID=SYND_STOCKTWITS_TWEET_2_2810456_TEASER_26895

0 · Reply

MetroMyth Dec. 27 at 3:20 PM

$MED Positioning reflects caution while awaiting confirmable progress; customer retention trends will be critical to monitor — improving transparency could compress perceived risk. Patience helps only if fundamentals keep strengthening.

0 · Reply

ZacksResearch Dec. 24 at 7:24 PM

$MED struggles with a 36.2% revenue drop — is recovery in sight? 📉 👥 Coach base shrinks by 35%, impacting sales 🛠️ Rightsizing actions in place to stabilize margins 📈 Expected inflection point in Q4 of fiscal 2025 as initiatives kick in Discover the full story here 👉 https://www.zacks.com/stock/news/2808820/medifasts-third-quarter-revenue-fell-36-is-stabilization-near?cid=sm-stocktwits-2-2808820-body-26325&ADID=SYND_STOCKTWITS_TWEET_2_2808820_BODY_26325

0 · Reply

ZacksResearch Dec. 24 at 6:24 PM

$MED just saw Q3 revenue drop 36% — but is the bottom finally forming? ⚠️ Medifast’s revenue plunged as its coach base shrank, yet restructuring and productivity initiatives are aimed at stabilizing results by late 2025. The setup is ugly, but the turnaround angle is clearly being framed. See whether stabilization is realistic 👉 https://www.zacks.com/stock/news/2808820/medifasts-third-quarter-revenue-fell-36-is-stabilization-near?cid=sm-stocktwits-2-2808820-teaser-26295&ADID=SYND_STOCKTWITS_TWEET_2_2808820_TEASER_26295

0 · Reply

Market Cap	125.74M
Revenue (ttm)	602.46M
Net Income (ttm)	2.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.35%
Debt to Equity Ratio	0.00

Volume	363,500
Avg Vol	257,248
Day's Range	N/A - N/A
Shares Out	10.99M
Stochastic %K	46%
Beta	0.48
Analysts	Hold
Price Target	$15.00